Signal from the log
Breye Therapeutics
67,5 M€ · Series A · Denmark · Biotech
Breye Therapeutics, à Copenhague, développe le danegaptide, un comprimé qui protège les petits vaisseaux de la rétine chez les diabétiques, avant que la rétinopathie ne devienne sévère. Les traitements actuels sont des injections dans l'œil, réservées aux formes avancées. Un essai de phase 2 doit commencer en 2027.
Verified
Announced on , logged by the watch of 29 September 2026.
- Operation
- Funding round
- Announced amount
- 67,5 M€
- Stage
- Series A
- Country
- Denmark
- Sector
- Biotech
What the log says
Editorial note, in French
Communiqué ouvert, montant relu et fonds nommés.
The investors
Led by Mission BioCapital , Novo Holdings , with Sound Bioventures , Ljungström family office , Innovestor Life Science , EIFO , Catalyze Capital , Modi Ventures , Pappas Capital
Provenance
Source eu-startups,sifted
Logged on 29 September 2026
Description Written in French during the watch run. Written during the watch run, after reading the issuer's press release or the source article.
Verification Amounts and fund names were double checked against the issuer's press release or an official filing.
What this status means
Verified The press release was opened: amount double checked, funds named. The article remains to be written.
The rule A signal is never removed from the log. A round set aside stays readable with its reason, because a collection you cannot reread is a collection you cannot correct.